1. Home
  2. |Insights
  3. |COVID-19 Roundtable Discussion: Practical Guidance for Legal Departments, Business Leaders, and Boards

COVID-19 Roundtable Discussion: Practical Guidance for Legal Departments, Business Leaders, and Boards

Webinar | 03.10.20, 8:00 AM EDT - 9:00 AM EDT

Register

Please join us for a webinar that will discuss some of the key business and legal issues that companies are navigating in connection with the Coronavirus (COVID-19) and its cross-jurisdictional impacts. Topics will include supply chain disruption, labor and employment, employee mobility, commercial contracts, government contracts, health care, insurance coverage, privacy, crisis management and continuity of operations, and more. 


The format of the webinar will be a roundtable discussion led by members of Crowell & Moring’s COVID-19 multi-disciplinary working group.  The team includes lawyers with senior government, industry and legal experience relevant to this rapidly evolving situation.  We will address real time issues and concerns and provide practical guidance and approaches. We hope you will join our team for this free webinar.


Speakers

  • Bryan Brewer, Partner, Washington, D.C.
  • Michelle Coleman, Counsel, Washington, D.C.
  • Jodi Daniel, Partner, Washington, D.C.
  • Peter Eyre, Partner, Washington, D.C.
  • Laura Foggan, Partner, Washington, D.C.
  • Tom Gies, Partner, Washington, D.C.
  • Paul Rosen, Partner, Los Angeles
  • Nicole Simonian, Partner, Los Angeles
  • Evan Wolff, Partner, Washington, D.C.

For more information, please visit our Coronavirus Resources page.

Participants

Insights

Webinar | 12.10.26

The Third-Party Perspective: Protecting Payors’ Interests in Antitrust Investigations

The Trump administration has sharpened its focus on hospital systems as a key driver of rising health care costs, and the DOJ and FTC are actively patrolling for anticompetitive conduct and mergers that contribute to these rising costs. Managed care organizations are a critical source of evidence in these investigations and are likely to receive Civil Investigative Demands (CIDs), be contacted by agency staff, or may consider proactively engaging with antitrust authorities to address competitive concerns in their markets.

View All Insights